The Indian Pharmacopoeia Commission (IPC) has raised concerns regarding the painkiller Meftal, cautioning healthcare practitioners and patients about possible adverse reactions associated with its use. Meftal, a commonly prescribed medication for menstrual cramps and rheumatoid arthritis, has come under scrutiny following a drug safety alert issued by the IPC.
The drug, containing mefenamic acid, finds applications in treating various conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain. However, a recent preliminary analysis conducted by the Pharmacovigilance Programme of India (PvPI) database has highlighted instances of adverse drug reactions associated with Meftal, specifically citing the occurrence of drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.
In response to this discovery, the IPC has advised vigilance and close monitoring of potential adverse reactions linked to the use of Meftal. The issued alert on November 30 urged healthcare professionals, patients, and consumers to be particularly watchful for signs of the aforementioned adverse drug reaction (ADR). If encountered, individuals are encouraged to report such reactions promptly to the national coordination center of the PvPI under the IPC. Reporting can be done via the IPC website (www.ipc.gov.in), through the Android mobile app ADR PvPI, or by contacting the PvPI Helpline No. 1800-180-3024.
The IPC, an autonomous institution operating under the Ministry of Health, assumes the responsibility of establishing standards for all drugs manufactured, sold, and consumed in India. This safety alert serves as a proactive measure to ensure the well-being and safety of individuals using pharmaceuticals across the country.
This advisory underscores the importance of vigilant monitoring of medications and the proactive reporting of adverse drug reactions to ensure prompt and appropriate action to safeguard public health.
Sources By Agencies
